Latest Information Update: 07 Jul 2006
At a glance
- Originator Novo Nordisk
- Mechanism of Action Glucagon receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 28 Apr 2005 Discontinued - Phase-I for Type-2 diabetes mellitus in Denmark (PO)
- 21 Feb 2003 Phase-I clinical trials in Type-2 diabetes mellitus in Denmark (PO)